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LETTERS TO THE EDITOR
ANOVA for repeated measures (with log conversion ifDoes choice of membrane or
the data were not normally distributed) would have been
more appropriate.modality impact oxidant stress
To summarize, the data reported by Satoh et al fail
to identify a lower oxidant potential for vitamin E-coatedin hemodialysis therapy?
membranes compared to synthetic polysulfone.
H. Feidhlim WoodsTo the Editor: There is mounting evidence for disor-
Hong Kongdered oxidative and glycoxidative chemistry in uremia
that may contribute to cardiovascular morbidity and mor- Correspondence to H. Feidhlim Woods, M.B., M.R.C.P., Vice Presi-
dent, Medical & Marketing Department, Fresenius Medical Care Asiatality. It is important, therefore, to understand whether
Pacific, 5101 Sun Hung Kai Centre, 30 Harbour Road, Wanchai, Hongprescriptive decisions in hemodialysis therapy, such as Kong, SAR.
choice of membrane or modality, impact oxidant stress.
In a crossover study, Satoh et al [1] describe increased
levels of malondialdehyde (MDA), advanced glycation REFERENCES
end products (AGE), and 8-hydroxy 2-deoxyguanosine 1. Satoh M, Yamasaki Y, Nagake Y, et al: Oxidative stress is reduced
(8-OHdG) markers of lipid, protein, and DNA oxidation, by the long-term use of vitamin E-coated dialysis filters. Kidney Int
59:1943–1950, 2001respectively, when patients were dialyzed with a high
2. Tarng DC, Huang TP, Liu TY, et al: Effect of vitamin E-bondedpermeability polysulfone [Clirans PS (CL-PS), Terumo membrane on the 8-hydroxy 2-deoxyguanosine level in leukocyte
Corp., Toyko, Japan] compared to a vitamin E-coated DNA of hemodialysis patients. Kidney Int 58:790–799, 2000
low permeability membrane [Clirans EE-N (CL-EE),
Terumo Corp.]. In addition, during a single dialysis with
CL-PS, the post-dialysis concentration of AGE and
8-OHdG rose, whereas the concentration of 2-micro- Familial cases of
globulin fell. AGE and 8-OHdG levels pre- and post-
dialysis with the CL-EE membrane remained essentially Berger’s disease and
unchanged. These data are at variance with the data of
Tarng et al [2], who showed similar effects of 8-OHdG anaphylactoid purpura
of polysulfone and polymethylmetacrylate (PMMA) dia-
lyzers when compared to the vitamin E-coated mem-
To the Editor: Davin, Berge and Weening recentlybrane.
published a review pointing out the similarities and theIn the Methods section Satoh et al fail to describe
differences between IgA nephropathy (IgAN) and He-their estimate of the molecular size of the species of
noch-Scho¨nlein purpura (HSP) nephritis [1]. They re-AGE and 8-OHdG detected by their assay methods. Nor
ported that IgAN and HSP could “be related diseasesdo they correct solute concentration for hemoconcentra-
since both may be encountered consecutively in the sametion due to ultrafiltration. Since the low permeability
patient, have been described in identical twins and bearCL-EE membrane could not have been expected to clear
identical pathological and biological abnormalities.”significant quantities of AGE, the inference must be that,
We would like to report on the results of the collabora-during a single dialysis session, CL-PS caused a higher
tive study of the Society of Nephrology (France) carriedgeneration of AGE (and 8-OHdG) than the CL-EE. In
out in the late 1980s [2, 3]. This survey revealed 40 fami-light of the known time dependency for protein glycation
lies with two or three members having biopsy-confirmedand DNA oxidation, this seems far-fetched.
IgAN. In five of these 40 families, one or two additionalIn Figures 2 and 3 (AGE concentration and 8-OHdG
relatives presented with HSP, with or without renal in-concentration, respectively, during the crossover study),
volvement: a father and son with IgAN, and a second sonthe pattern of change of the mean values and the stan-
with HSP; a father and two sons with IgAN, and a thirddard deviations for the means are highly suggestive of
son’s daughter with HSP; an uncle and nephew with IgAN,reversion to the mean. The statistic used (Mann-Whit-
and an uncle’s sister with HSP; two sisters with HSP, andney rank sum) is inappropriate. A method such as GLM
a brother and a nephew with IgAN; and an uncle and
niece with IgAN, and a nephew with HSP.
In addition, there were 18 other families in which 2001 by the International Society of Nephrology
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one member only had IgAN and one (or two relatives) tive treatments were very similar (i.e., 1.14 vs. 0.94 ng/mL/
had HSP. hour). Second, sodium intake was high and uncontrolled,
In our opinion, the possibility of such familial cases of allowing a lower baseline sodium excretion (intake)
IgAN and HSP can also be considered as another link before losartan treatment compared to placebo treat-
between the two diseases. ment ( sodium excretion 37 mEq/24 hours) and a higher
sodium excretion at the end of losartan treatment ( so-
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Therefore, the most plausible explanation for the
plasma renin data obtained by Agarwal [1] may be meth-REFERENCES
odological shortcomings and random fluctuations, but
1. David J-C, ten Berge IJ, Weening JJ: What is the difference be- no real effect of losartan. Parenthetically, this could
tween IgA nephropathy and Henoch-Scho¨nlein purpura nephritis?
also hold true for the results of glomerular filtrationKidney Int 59:823–834, 2001
2. Levy M, French Cooperative Group of the Society of Nephrol- rate (GFR) measurements, where GFR decreased (ran-
ogy: Familial cases of Berger’s disease and anaphylactoid purpura: domly) by 5 mL/min during placebo treatment (from 69
More frequent than previously thought. Am J Med 87:246–248, 1989
to 64 mL/min) and increased by 5 mL/min during losar-3. Levy M: Multiplex families in IgA nephropathy. Contrib Nephrol
104:46–53, 1993 tan treatment (from 63 to 68 mL/min) [1].
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expression severalfold from baseline [2]. Furthermore,
both 100 mg losartan and 80 mg quinalapril given for 10
days at this constant dose increased plasma renin activity
Reply from the author3- to 4-fold in 25 normotensive subjects on a controlled
I agree with Kra¨mer et al that the increase in plasma(low) sodium intake [3]. Finally, Stergiou et al recently
renin activity (PRA) with add-on losartan therapy wasdemonstrated that the addition of 80 mg valsartan for 5
unexpected [1]. However, I am unaware of any data inweeks to a maximal dose of chronic benazepril (20 mg
the population of patients that was studied to refute thosefor 6 weeks) significantly increased plasma renin activity
findings. Brown, Agirbasli, and Vaughan compared an-in 20 patients with primary hypertension [4].
giotensin-converting enzyme (ACE) inhibitors with an-The above results of Agarwal [1] may be explained by
giotensin II receptor blocker but did not study the combi-several shortcomings of this study. First, baseline plasma
nation in normotensive, sodium-restricted volunteers [2].renin activity before losartan treatment was 204% (!) of
In the study by Stergiou et al, benazepril was used in abaseline plasma renin activity before placebo treatment,
submaximal dose (20 mg/day) in patients with essentialwhereas plasma renin activities at the end of the respec-
hypertension [3]. In contrast, our patients received lisino-
pril for an average of 18 months in a dose of 40 mg/day
prior to participation in the trial. Such a dose is truly max- 2001 by the International Society of Nephrology
